Creating vaccines to protect against emerging bunyaviruses.
Official title: Development of recombinant VSV vaccines for emerging bunyaviruses
Funded at Advac Therapeutic, LLC · NIH-10828394 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people from a serious virus called SFTSV, which can spread from animals to humans, using a safe and tested method that has shown promise in the past.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Advac Therapeutic, LLC NIH-funded |
| Lab location | 1 site (Phoenixville, UNITED STATES) |
| Project start | April 13, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $276,715 |
| NIH project number | 5R41AI174426-02 |
| Project ID | NIH-10828394 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living in or traveling to areas where SFTSV is known to circulate, particularly in Eastern Asia.
✕Less likely to help
Patients who are not at risk of exposure to SFTSV or who live in regions where the virus is not present may not benefit from this research.
What this research studies
This research focuses on developing a vaccine using a modified virus to protect against severe fever with thrombocytopenia syndrome virus (SFTSV), a dangerous bunyavirus that can be transmitted from animals to humans. The approach involves using a recombinant vesicular stomatitis virus (rVSV) platform, which has been shown to be effective and safe in previous applications. By targeting this virus, the research aims to enhance preparedness against potential outbreaks, especially in regions where the virus is prevalent.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the risk of severe illness and death from SFTSV infections.
How similar studies have gone: Previous research using similar vaccine platforms has shown promise in developing effective vaccines for other viral infections, indicating a potential for success in this approach.
Where this research is happening
-
Advac Therapeutic, LLC
Phoenixville, United States Active
Researchers
- Principal investigator: Bates, Paul — Advac Therapeutic, LLC
- Study coordinator: Bates, Paul
Related research
Other NIH-funded projects on the same topics.
-
Developing a new treatment for lung injury caused by pneumonia
This study is looking at a new way to help people, especially kids and older adults, recover from serious lung problems caused by bacterial pneumonia by using tiny molecules called microRNAs to heal damaged lung cells.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.